Policy Analysis: Life Sciences, Policy
Published:

EU-US plans for joint funding of rare diseases research unveiled to industry

A new transatlantic alliance showcased its ambition to develop diagnostics for 8,000 rare diseases and double the number of registered Orphan drugs for rare conditions by 2020, at the Biotechnology Industry Organization (BIO) meeting in Washington

The European Commission's Director of Public Health Andrzej Rys said rare diseases will continue to be a priority in the next research programme, Horizon 2020 Photo: Charité, Berlin

The European Commission and the US National Institutes of Health (NIH) is putting together a jointly-funded programme of research to capitalise on advances in genomics and speed up the development of diagnostics and treatments for rare diseases.

The International Rare Disease Research Consortium (IRDiRC) set up by the Commission and the NIH to drive the plan, will hold a meeting in Montreal, Canada in October to finalise its research agenda, following two earlier meetings to set objectives...



Related subjects: Biotechnology, European Commission, European Union, USA, personalised healthcare

The 2015 Science|Business Annual Summit
The Science|Business Annual Summit brings together leaders from research, industry and policy to debate current and future trends needed to unleash Europe’s technological potential.
Barcelona - 20 November 2015
The future of manufacturing: Industry 4.0 (Date to be confirmed)
A Science|Business public conference
Brussels - 01 October 2015
The Bioeconomy Challenge: Producing more from less
A Science|Business high-level roundtable
Brussels - 29 September 2015
BIG SCIENCE: What’s It Worth?
The world spends millions a year on telescopes, synchrotrons, colliders, DNA databases and other ‘big science’ projects. What does it get for that money?